Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mikazane, Helena"'
Autor:
Kakurina, Natalja, Kadisa, Anda, Lejnieks, Aivars, Mikazane, Helena, Kozireva, Svetlana, Murovska, Modra
Publikováno v:
In Medicina 2015 51(1):18-24
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Won Park, Hrycaj, Pawel, Jeka, Slawomir, Kovalenko, Volodymyr, Lysenko, Grygorii, Miranda, Pedro, Mikazane, Helena, Gutierrez-Ureña, Sergio, MieJin Lim, Yeon-Ah Lee, Sang Joon Lee, HoUng Kim, Dae Hyun Yoo, Jürgen Braun
Publikováno v:
Annals of the Rheumatic Diseases; Oct2013, Vol. 72 Issue 10, p1605-1612, 8p, 1 Diagram, 4 Charts, 1 Graph
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Zhao, Sizheng; Chadwick, Laura; Mysler, Eduardo; Moots, Robert J. (2018) Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. En: Curr Rheumatol Rep. pp. 57-57; Consultado en: 2020/03/08/23:16:12. Disponible en: http://dx.doi.org/10.1007/s11926-018-0769-6.
Reimold, Andreas M. (2012) The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. En: Open Access Rheumatology: Research and Reviews. Vol. 4; pp. 33-47; 1179-156X; Disponible en: 10.2147/OARRR.S14569.
Chen, Y.-F.; Jobanputra, P.; Barton, P.; Jowett, S.; Bryan, S.; Clark, W.; Fry-Smith, A.; Burls, A. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. En: Health Technology Assessment (Winchester, England). Vol. 10; No. 42; pp. iii-iv, xi-xiii, 1-229; 1366-5278; Disponible en: 10.3310/hta10420.
Cvetkovic, Risto S.; Scott, Lesley J. (2006) Adalimumab: a review of its use in adult patients with rheumatoid arthritis. En: BioDrugs. pp. 293-311; Consultado en: 2020/03/09/00:13:53. Disponible en: https://pesquisa.bvsalud.org/portal/resource/es/mdl-17025376.
Markus, Richard; McBride, Helen J.; Ramchandani, Monica; Chow, Vincent; Liu, Jennifer; Mytych, Dan; Fanjiang, Gary (2019) A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501. En: Advances in Therapy. Vol. 36; No. 8; pp. 1833-1850; 1865-8652; Disponible en: 10.1007/s12325-019-00979-6.
Cohen, Stanley; Genovese, Mark C.; Choy, Ernest; Perez-Ruiz, Fernando; Matsumoto, Alan; Pavelka, Karel; Pablos, Jose L.; Rizzo, Warren; Hrycaj, Pawel; Zhang, Nan; Shergy, William; Kaur, Primal (2017) Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. En: Annals of the Rheumatic Diseases. Vol. 76; No. 10; pp. 1679-1687; 1468-2060; Disponible en: 10.1136/annrheumdis-2016-210459.
Cohen, Stanley; Pablos, Jose L.; Pavelka, Karel; Müller, Gerard Anton; Matsumoto, Alan; Kivitz, Alan; Wang, Hui; Krishnan, Eswar (2019) An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. En: Arthritis Research & Therapy. Vol. 21; No. 1; pp. 84 1478-6362; Disponible en: 10.1186/s13075-019-1857-3.
Pelechas, Eleftherios; Voulgari, Paraskevi V.; Drosos, Alexandros A. (2018) ABP 501 for the treatment of rheumatoid arthritis. En: Expert Opinion on Biological Therapy. Vol. 18; No. 3; pp. 317-322; 1744-7682; Disponible en: 10.1080/14712598.2018.1430760.
Sivendran, Renuka; Ramírez, José; Ramchandani, Monica; Liu, Jennifer (2018) Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab. En: Immunotherapy. Vol. 10; No. 11; pp. 1011-1021; 1750-7448; Disponible en: 10.2217/imt-2018-0040.
Liu, Jennifer; Eris, Tamer; Li, Cynthia; Cao, Shawn; Kuhns, Scott (2016) Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. En: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. Vol. 30; No. 4; pp. 321-338; 1179-190X; Disponible en: 10.1007/s40259-016-0184-3.
Kaur, Primal; Chow, Vincent; Zhang, Nan; Moxness, Michael; Kaliyaperumal, Arunan; Markus, Richard (2017) A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. En: Annals of the Rheumatic Diseases. Vol. 76; No. 3; pp. 526-533; 1468-2060; Disponible en: 10.1136/annrheumdis-2015-208914.
Norman, Peter (2017) Humira®: recent developments. En: Pharmaceutical Patent Analyst. Vol. 6; No. 3; pp. 89-90; 2046-8962; Disponible en: 10.4155/ppa-2017-0012.
Advanced Search | Cochrane Library. Consultado en: 2020/03/23/13:47:36. Disponible en: https://www.cochranelibrary.com/advanced-search.
Immunogenicity associated with a transition from adalimumab reference product to ABP 501 in patients with rheumatoid arthritis | Cochrane Library. Consultado en: 2020/03/23/14:25:19. Disponible en: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01647590/full.
Velayudhan, Jyoti; Chen, Yuh-feng; Rohrbach, Amanda; Pastula, Christina; Maher, Gwen; Thomas, Heather; Brown, Ryan; Born, Teresa L. (2016) Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab. En: BioDrugs. Vol. 30; No. 4; pp. 339-351; 1179-190X; Consultado en: 2020/03/30/01:58:25. Disponible en: https://doi.org/10.1007/s40259-016-0185-2. Disponible en: 10.1007/s40259-016-0185-2.
González, Martha Lucía; Rueda, Jorge; González, Herman; Cantor, Erika; Martínez, Alexander (2016) Artritis reumatoide temprana: resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia. En: Revista Colombiana de Reumatología. Vol. 23; No. 3; pp. 148-154; 0121-8123; Consultado en: 2020/04/09/15:59:24. Disponible en: http://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-artritis-reumatoide-temprana-resultados-clinicos-S0121812316300275. Disponible en: 10.1016/j.rcreu.2016.04.004.
RODRÍGUEZ CORTES, LAURA ANDREA (2015) EVALUACION ECONOMICA DE MEDICAMENTOS BIOLOGICOS UTILIZADOS EN EL TRATAMIENTO DE TERCERA LINEA PARA ARTRITIS REUMATOIDE EN COLOMBIA. : Tesis Grado, UNIVERSIDAD DE CIENCIAS APLICADAS Y AMBIENTALES; Disponible en: https://repository.udca.edu.co/bitstream/11158/330/1/EVALUACION%20ECONOMICA%20DE%20MEDICAMENTOS%20BIOLOGICOS%20UTILIZADOS%20EN%20EL%20TRATAMIENTO%20DE%20TERCERA%20LINEA%20PAR.pdf.
Gabriel, Sherine E.; Michaud, Kaleb (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. En: Arthritis Research & Therapy. Vol. 11; No. 3; pp. 229 1478-6362; Disponible en: 10.1186/ar2669.
Combe, B.; Lukas, C.; Morel, J. (2016) Artritis reumatoide del adulto: estrategias terapéuticas. En: EMC. Vol. 49; No. 2; pp. 1-24; 1286-935X; Consultado en: 2020/04/09/16:07:44. Disponible en: http://www.sciencedirect.com/science/article/pii/S1286935X16782438. Disponible en: 10.1016/S1286-935X(16)78243-8.
Grupo GUIPCAR de trabajo de la GPC para el Manejo de Pacientes con Artritis Reumatoide (2019) Guía de Práctica Clínica para el Manejo de los Pacientes con Artritis Reumatoide. En: SER. Consultado en: 2020/04/09/16:08:59. Disponible en: https://www.ser.es/guipcar/.
Malhan, Simten; Pay, Salih; Ataman, Sebnem; Dalkilic, Ediz; Dinc, Ayhan; Erken, Eren; Ertenli, Ihsan; Ertugrul, Esin; Gogus, Feride; Hamuryudan, Vedat; Inanc, Murat; Karaarslan, Yasar; Karadag, Omer; Karakoc, Yuksel; Keskin, Goksal; Kisacik, Bunyamin; Kiraz, Sedat; Oksel, Fahrettin; Oksuz, Ergun; Pirildar, Timur; Sari, Ismail; Soy, Mehmet; Senturk, Taskin; Taylan, Ali (2012) The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. En: Clinical and Experimental Rheumatology. Vol. 30; No. 2; pp. 202-207; 0392-856X
Gulácsi, László; Brodszky, Valentin; Baji, Petra; Kim, HoUng; Kim, Su Yeon; Cho, Yu Young; Péntek, Márta (2015) Biosimilars for the management of rheumatoid arthritis: economic considerations. En: Expert Review of Clinical Immunology. Vol. 11 Suppl 1; pp. S43-52; 1744-8409; Disponible en: 10.1586/1744666X.2015.1090313.
Mysler, Eduardo; Pineda, Carlos; Horiuchi, Takahiko; Singh, Ena; Mahgoub, Ehab; Coindreau, Javier; Jacobs, Ira (2016) Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. En: Rheumatology International. Vol. 36; No. 5; pp. 613-625; 1437-160X; Disponible en: 10.1007/s00296-016-3444-0.
Collazo Herrera, Manuel; Sosa Lorenzo, Irma (2011) La farmacoeconomía: Debe ser de interés para evaluar la eficiencia en la toma de decisiones?. En: Revista Colombiana de Ciencias Químico. Vol. 40; No. 1; pp. 54-66; 0034-7418; Consultado en: 2020/04/09/16:30:09. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0034-74182011000100004&lng=en&nrm=iso&tlng=es.
Cohen, Hillel P.; Blauvelt, Andrew; Rifkin, Robert M.; Danese, Silvio; Gokhale, Sameer B.; Woollett, Gillian (2018) Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. En: Drugs. Vol. 78; No. 4; pp. 463-478; 1179-1950; Disponible en: 10.1007/s40265-018-0881-y.
Messori, Andrea; Trippoli, Sabrina; Marinai, Claudio (2017) Network meta-analysis as a tool for improving the effectiveness assessment of biosimilars based on both direct and indirect evidence: application to infliximab in rheumatoid arthritis. En: European Journal of Clinical Pharmacology. Vol. 73; No. 4; pp. 513-514; 1432-1041; Disponible en: 10.1007/s00228-016-2177-z.
Larráyoz, Beatriz; Concepto, regulación y controversias en su utilización. pp. 11
Londoño, John; Peláez-Ballestas, Ingris; Cuervo, Francy; Angarita, Ignacio; Giraldo, Rodrigo; Rueda, Juan Camilo; Ballesteros, Jesús Giovanny; Baquero, Roberto; Forero, Elías; Cardiel, Mario; Saldarriaga, Eugenia; Vásquez, Andrés; Arias, Sofía; Valero, Lina; González, Camilo; Ramírez, Javier; Toro, Carlos; Santos, Ana María (2018) Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. En: Revista Colombiana de Reumatología. Vol. 25; No. 4; pp. 245-256; 0121-8123; Consultado en: 2020/04/09/16:39:30. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0121-81232018000400245&lng=en&nrm=iso&tlng=es. Disponible en: 10.1016/j.rcreu.2018.08.003.
Sharma, Shefali Khanna (2017) Use of Biologics and Biosimilars in Rheumatology. En: The Journal of the Association of Physicians of India. Vol. 65; No. 5 Suppl; pp. 9-14; 0004-5772
Kowalik, Krzysztof; Węgierska, Małgorzata; Barczyńska, Tacjana; Jeka, Sławomir (2018) Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. En: Reumatologia. Vol. 56; No. 6; pp. 340-345; 0034-6233; Disponible en: 10.5114/reum.2018.80710.
Weinblatt, M E; Keystone, E C; Furst, D E; Kavanaugh, A F; Chartash, E K; Segurado, O G (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. En: Annals of the Rheumatic Diseases. Vol. 65; No. 6; pp. 753-759; 0003-4967; Consultado en: 2020/04/09/16:54:36. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798163/. Disponible en: 10.1136/ard.2005.044404.
Bang, Lynne M.; Keating, Gillian M. (2004) Adalimumab. En: BioDrugs. Vol. 18; No. 2; pp. 121-139; 1179-190X; Consultado en: 2020/04/09/17:00:27. Disponible en: https://doi.org/10.2165/00063030-200418020-00005. Disponible en: 10.2165/00063030-200418020-00005.
Carmona, Loreto; Cross, Marita; Williams, Ben; Lassere, Marissa; March, Lyn (2010) Rheumatoid arthritis. En: Best Practice & Research. Clinical Rheumatology. Vol. 24; No. 6; pp. 733-745; 1532-1770; Disponible en: 10.1016/j.berh.2010.10.001.
Serra López-Matencio, José M.; Morell Baladrón, Alberto; Castañeda, Santos (2017) Fármacos biosimilares: un nuevo escenario en las terapias biológicas. En: Reumatología Clínica. Vol. 13; No. 5; pp. 287-293; 1699-258X; Consultado en: 2020/04/10/14:49:03. Disponible en: http://www.sciencedirect.com/science/article/pii/S1699258X16300572. Disponible en: 10.1016/j.reuma.2016.05.013.
El medicamento contra la artritis Humira, el más vendido del mundo. Consultado en: 2020/04/10/16:24:13. Disponible en: https://www.plantadoce.com/entorno/el-medicamento-contra-la-artritis-humira-el-mas-vendido-del-mundo.html.
Breedveld, Ferdinand C.; Weisman, Michael H.; Kavanaugh, Arthur F.; Cohen, Stanley B.; Pavelka, Karel; van Vollenhoven, Ronald; Sharp, John; Perez, John L.; Spencer-Green, George T. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. En: Arthritis and Rheumatism. Vol. 54; No. 1; pp. 26-37; 0004-3591; Disponible en: 10.1002/art.21519.
Fiorino, Gionata; Gilardi, Daniela; Correale, Carmen; Furfaro, Federica; Roda, Giulia; Loy, Laura; Argollo, Marjorie; Allocca, Mariangela; Peyrin-Biroulet, Laurent; Danese, Silvio (2019) Biosimilars of adalimumab: the upcoming challenge in IBD. En: Expert Opinion on Biological Therapy. Vol. 19; No. 10; pp. 1023-1030; 1471-2598; Consultado en: 2020/05/01/21:59:52. Disponible en: https://doi.org/10.1080/14712598.2019.1564033. Disponible en: 10.1080/14712598.2019.1564033.
Azevedo, Valderilio Feijó; Babini, Alejandra; Caballero-Uribe, Carlo V.; Castañeda-Hernández, Gilberto; Borlenghi, Cecilia; Jones, Heather E. (2019) Practical Guidance on Biosimilars, With a Focus on Latin America. En: Journal of Clinical Rheumatology. Vol. 25; No. 2; pp. 91-100; 1076-1608; Consultado en: 2020/05/02/16:12:27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392209/. Disponible en: 10.1097/RHU.0000000000000881.
Fondo Colombiano de enfermedades de alto costo (CAC) (2020) Situación de la Artritis Reumatoide en Colombia 2019.
Agencia Europea de Medicamentos; Comision Europea (2019) Los biosimilares en la UE. Guia informativa para profesionales sanitarios. En: 2019. pp. 40
Schiff, Michael; Weinblatt, Michael E.; Valente, Robert; Heijde, Désirée van der; Citera, Gustavo; Elegbe, Ayanbola; Maldonado, Michael; Fleischmann, Roy (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. En: Annals of the Rheumatic Diseases. Vol. 73; No. 1; pp. 86-94; 0003-4967, 1468-2060; Consultado en: 2021/02/06/15:59:28. Disponible en: https://ard.bmj.com/content/73/1/86. Disponible en: 10.1136/annrheumdis-2013-203843.
Fleischmann, Roy; Mysler, Eduardo; Hall, Stephen; Kivitz, Alan J.; Moots, Robert J.; Luo, Zhen; DeMasi, Ryan; Soma, Koshika; Zhang, Richard; Takiya, Liza; Tatulych, Svitlana; Mojcik, Christopher; Krishnaswami, Sriram; Menon, Sujatha; Smolen, Josef S.; ORAL Strategy investigators (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. En: Lancet (London, England). Vol. 390; No. 10093; pp. 457-468; 1474-547X; Disponible en: 10.1016/S0140-6736(17)31618-5.
Smolen, Josef S.; Burmester, Gerd-Rüdiger; Combe, Bernard; Curtis, Jeffrey R.; Hall, Stephen; Haraoui, Boulos; van Vollenhoven, Ronald; Cioffi, Christopher; Ecoffet, Cécile; Gervitz, Leon; Ionescu, Lucian; Peterson, Luke; Fleischmann, Roy (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. En: Lancet (London, England). Vol. 388; No. 10061; pp. 2763-2774; 1474-547X; Disponible en: 10.1016/S0140-6736(16)31651-8.
Silman, A. J.; Hochberg, M. C. (2001) Epidemiology of the rheumatic diseases. En: Epidemiology of the rheumatic diseases. No. Ed. 2; Consultado en: 2021/02/06/16:17:19. Disponible en: https://www.cabdirect.org/cabdirect/abstract/20033069305.
Zeidler, Henning (2012) The need to better classify and diagnose early and very early rheumatoid arthritis. En: The Journal of Rheumatology. Vol. 39; No. 2; pp. 212-217; 0315-162X; Disponible en: 10.3899/jrheum.110967.
Fernández-Ávila, Daniel G.; Rincón-Riaño, Diana N.; Bernal-Macías, Santiago; Gutiérrez Dávila, Juan M.; Rosselli, Diego (2019) Prevalencia de la artritis reumatoide en Colombia según información del Sistema Integral de Información de la Protección Social. En: Revista Colombiana de Reumatología. Vol. 26; No. 2; pp. 83-87; 01218123; Consultado en: 2021/02/06/16:40:56. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0121812319300167. Disponible en: 10.1016/j.rcreu.2019.01.003.
Funovits, Julia; Aletaha, Daniel; Bykerk, Vivian; Combe, Bernard; Dougados, Maxime; Emery, Paul; Felson, David; Hawker, Gillian; Hazes, Joanna M.; Huizinga, Tom; Kay, Jonathan; Kvien, Tore K.; Smolen, Josef S.; Symmons, Deborah; Tak, Paul P.; Silman, Alan (2010) The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. En: Annals of the Rheumatic Diseases. Vol. 69; No. 9; pp. 1589-1595; 1468-2060; Disponible en: 10.1136/ard.2010.130310.
Aletaha, Daniel; Neogi, Tuhina; Silman, Alan J.; Funovits, Julia; Felson, David T.; Bingham, Clifton O.; Birnbaum, Neal S.; Burmester, Gerd R.; Bykerk, Vivian P.; Cohen, Marc D.; Combe, Bernard; Costenbader, Karen H.; Dougados, Maxime; Emery, Paul; Ferraccioli, Gianfranco; Hazes, Johanna M. W.; Hobbs, Kathryn; Huizinga, Tom W. J.; Kavanaugh, Arthur; Kay, Jonathan; Kvien, Tore K.; Laing, Timothy; Mease, Philip; Ménard, Henri A.; Moreland, Larry W.; Naden, Raymond L.; Pincus, Theodore; Smolen, Josef S.; Stanislawska-Biernat, Ewa; Symmons, Deborah; Tak, Paul P.; Upchurch, Katherine S.; Vencovský, Jirí; Wolfe, Frederick; Hawker, Gillian (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. En: Arthritis and Rheumatism. Vol. 62; No. 9; pp. 2569-2581; 1529-0131; Disponible en: 10.1002/art.27584.
Bizzaro, Nicola; Bartoloni, Elena; Morozzi, Gabriella; Manganelli, Stefania; Riccieri, Valeria; Sabatini, Paola; Filippini, Matteo; Tampoia, Marilina; Afeltra, Antonella; Sebastiani, Giandomenico; Alpini, Claudia; Bini, Vittorio; Bistoni, Onelia; Alunno, Alessia; Gerli, Roberto; the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group) (2013) Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. En: Arthritis Research & Therapy. Vol. 15; No. 1; pp. R16 1478-6354; Consultado en: 2021/02/06/17:00:33. Disponible en: http://arthritis-research.biomedcentral.com/articles/10.1186/ar4148. Disponible en: 10.1186/ar4148.
Aletaha, Daniel; Alasti, Farideh; Smolen, Josef S. (2011) Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. En: Annals of the Rheumatic Diseases. Vol. 70; No. 11; pp. 1975-1980; 1468-2060; Disponible en: 10.1136/ard.2011.153734.
Singh, Jasvinder A.; Furst, Daniel E.; Bharat, Aseem; Curtis, Jeffrey R.; Kavanaugh, Arthur F.; Kremer, Joel M.; Moreland, Larry W.; O'Dell, James; Winthrop, Kevin L.; Beukelman, Timothy; Bridges, S. Louis; Chatham, W. Winn; Paulus, Harold E.; Suarez-Almazor, Maria; Bombardier, Claire; Dougados, Maxime; Khanna, Dinesh; King, Charles M.; Leong, Amye L.; Matteson, Eric L.; Schousboe, John T.; Moynihan, Eileen; Kolba, Karen S.; Jain, Archana; Volkmann, Elizabeth R.; Agrawal, Harsh; Bae, Sangmee; Mudano, Amy S.; Patkar, Nivedita M.; Saag, Kenneth G. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. En: Arthritis Care & Research. Vol. 64; No. 5; pp. 625-639; 2151-4658; Disponible en: 10.1002/acr.21641.
Linden, Michael P. M. van der; Cessie, Saskia le; Raza, Karim; Woude, Diane van der; Knevel, Rachel; Huizinga, Tom W. J.; Mil, Annette H. M. van der Helm-van (2010) Long-term impact of delay in assessment of patients with early arthritis. En: Arthritis & Rheumatism. Vol. 62; No. 12; pp. 3537-3546; 1529-0131; Consultado en: 2021/02/06/17:11:19. Disponible en: http://onlinelibrary.wiley.com/doi/abs/10.1002/art.27692. Disponible en: https://doi.org/10.1002/art.27692.
Verstappen, S. M. M.; Jacobs, J. W. G.; van der Veen, M. J.; Heurkens, A. H. M.; Schenk, Y.; ter Borg, E. J.; Blaauw, A. a. M.; Bijlsma, J. W. J.; Utrecht Rheumatoid Arthritis Cohort study group (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). En: Annals of the Rheumatic Diseases. Vol. 66; No. 11; pp. 1443-1449; 0003-4967; Disponible en: 10.1136/ard.2007.071092.
Curtis, Jeffrey R.; Singh, Jasvinder A. (2011) Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. En: Clinical Therapeutics. Vol. 33; No. 6; pp. 679-707; 1879-114X; Disponible en: 10.1016/j.clinthera.2011.05.044.
Bernal-Camargo, Diana Rocío; Gaitán-Bohórquez, Julio César; León-Robayo, Édgar Iván (2018) Medicamentos biosimilares en Colombia: una revisión desde el consumo informado. En: Revista Ciencias de la Salud. Vol. 16; No. 2; pp. 311 2145-4507, 1692-7273; Consultado en: 2021/02/06/17:36:33. Disponible en: https://revistas.urosario.edu.co/index.php/revsalud/article/view/6772. Disponible en: 10.12804/revistas.urosario.edu.co/revsalud/a.6772.
Goel, Niti; Chance, Kamali (2017) Biosimilars in rheumatology: understanding the rigor of their development. En: Rheumatology (Oxford, England). Vol. 56; No. 2; pp. 187-197; 1462-0332; Disponible en: 10.1093/rheumatology/kew206.
Brinks, Vera; Jiskoot, Wim; Schellekens, Huub (2011) Immunogenicity of therapeutic proteins: the use of animal models. En: Pharmaceutical Research. Vol. 28; No. 10; pp. 2379-2385; 1573-904X; Disponible en: 10.1007/s11095-011-0523-5.
Jullien, D. (2012) Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis. En: Annales de Dermatologie et de Vénéréologie. Un œil neuf sur le psoriasis; Vol. 139; pp. S58-S67; 0151-9638; Consultado en: 2021/02/09/01:06:50. Disponible en: https://www.sciencedirect.com/science/article/pii/S0151963812701126. Disponible en: 10.1016/S0151-9638(12)70112-6.
Carrascosa, J. M. (2013) Inmunogenicidad en terapia biológica. Implicaciones en Dermatología. En: Actas Dermo-Sifiliográficas. Vol. 104; No. 6; pp. 471-479; 0001-7310; Consultado en: 2021/02/09/01:07:38. Disponible en: https://www.sciencedirect.com/science/article/pii/S0001731013000999. Disponible en: 10.1016/j.ad.2013.02.005.
Pani, Luca; Montilla, Simona; Pimpinella, Giuseppe; Bertini Malgarini, Renato (2013) Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. En: Expert Opinion on Biological Therapy. Vol. 13; No. 10; pp. 1343-1346; 1744-7682; Disponible en: 10.1517/14712598.2013.815722.
Kugler, Adriana D. (2000) The Incidence of Job Security Regulations on Labor Market Flexibility and Compliance in Colombia: Evidence from the 1990 Reform. Rochester, NY: Social Science Research Network; ID 1814666; Consultado en: 2021/03/14/14:29:00. Disponible en: https://papers.ssrn.com/abstract=1814666.
Kugler, Adriana D. (2000) The Incidence of Job Security Regulations on Labor Market Flexibility and Compliance in Colombia: Evidence from the 1990 Reform. Rochester, NY: Social Science Research Network; ID 1814666; Consultado en: 2021/03/14/14:29:41. Disponible en: https://papers.ssrn.com/abstract=1814666.
Targan, S. R.; Hanauer, S. B.; van Deventer, S. J.; Mayer, L.; Present, D. H.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. En: The New England Journal of Medicine. Vol. 337; No. 15; pp. 1029-1035; 0028-4793; Disponible en: 10.1056/NEJM199710093371502.
Maini, R. N.; Breedveld, F. C.; Kalden, J. R.; Smolen, J. S.; Davis, D.; Macfarlane, J. D.; Antoni, C.; Leeb, B.; Elliott, M. J.; Woody, J. N.; Schaible, T. F.; Feldmann, M. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. En: Arthritis and Rheumatism. Vol. 41; No. 9; pp. 1552-1563; 0004-3591; Disponible en: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.
St Clair, E. William; Wagner, Carrie L.; Fasanmade, Adedigbo A.; Wang, Benjamin; Schaible, Thomas; Kavanaugh, Arthur; Keystone, Edward C. (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. En: Arthritis and Rheumatism. Vol. 46; No. 6; pp. 1451-1459; 0004-3591; Disponible en: 10.1002/art.10302.
Anonymous (2018) Remsima. En: European Medicines Agency. Consultado en: 2021/05/26/01:08:01. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima.
Park, Won; Hrycaj, Pawel; Jeka, Slawomir; Kovalenko, Volodymyr; Lysenko, Grygorii; Miranda, Pedro; Mikazane, Helena; Gutierrez-Ureña, Sergio; Lim, MieJin; Lee, Yeon-Ah; Lee, Sang Joon; Kim, HoUng; Yoo, Dae Hyun; Braun, Jürgen (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. En: Annals of the Rheumatic Diseases. Vol. 72; No. 10; pp. 1605-1612; 0003-4967, 1468-2060; Consultado en: 2021/05/26/01:09:20. Disponible en: https://ard.bmj.com/content/72/10/1605. Disponible en: 10.1136/annrheumdis-2012-203091.
Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13. En: ACR Meeting Abstracts. Consultado en: 2021/05/26/01:10:27. Disponible en: https://acrabstracts.org/abstract/efficacy-and-safety-of-ct-p13-infliximab-biosimilar-over-two-years-in-patients-with-ankylosing-spondylitis-comparison-between-continuing-with-ct-p13-and-switching-from-infliximab-to-ct-p13/.
Goll, G. L.; Jørgensen, K. K.; Sexton, J.; Olsen, I. C.; Bolstad, N.; Haavardsholm, E. A.; Lundin, K. E. A.; Tveit, K. S.; Lorentzen, M.; Berset, I. P.; Fevang, B. T. S.; Kalstad, S.; Ryggen, K.; Warren, D. J.; Klaasen, R. A.; Asak, Ø; Baigh, S.; Blomgren, I. M.; Brenna, Ø; Bruun, T. J.; Dvergsnes, K.; Frigstad, S. O.; Hansen, I. M.; Hatten, I. S. H.; Huppertz-Hauss, G.; Henriksen, M.; Hoie, S. S.; Krogh, J.; Midtgard, I. P.; Mielnik, P.; Moum, B.; Noraberg, G.; Poyan, A.; Prestegård, U.; Rashid, H. U.; Strand, E. K.; Skjetne, K.; Seeberg, K. A.; Torp, R.; Ystrøm, C. M.; Vold, C.; Zettel, C. C.; Waksvik, K.; Gulbrandsen, B.; Hagfors, J.; Mørk, C.; Jahnsen, J.; Kvien, T. K. (2019) Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. En: Journal of Internal Medicine. Vol. 285; No. 6; pp. 653-669; 1365-2796; Disponible en: 10.1111/joim.12880.
Yoo, Dae Hyun; Prodanovic, Nenad; Jaworski, Janusz; Miranda, Pedro; Ramiterre, Edgar; Lanzon, Allan; Baranauskaite, Asta; Wiland, Piotr; Abud-Mendoza, Carlos; Oparanov, Boycho; Smiyan, Svitlana; Kim, HoUng; Lee, Sang Joon; Kim, SuYeon; Park, Won (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. En: Annals of the Rheumatic Diseases. Vol. 76; No. 2; pp. 355-363; 1468-2060; Disponible en: 10.1136/annrheumdis-2015-208786.
Yoo, Dae Hyun; Hrycaj, Pawel; Miranda, Pedro; Ramiterre, Edgar; Piotrowski, Mariusz; Shevchuk, Sergii; Kovalenko, Volodymyr; Prodanovic, Nenad; Abello-Banfi, Mauricio; Gutierrez-Ureña, Sergio; Morales-Olazabal, Luis; Tee, Michael; Jimenez, Renato; Zamani, Omid; Lee, Sang Joon; Kim, HoUng; Park, Won; Müller-Ladner, Ulf (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. En: Annals of the Rheumatic Diseases. Vol. 72; No. 10; pp. 1613-1620; 1468-2060; Disponible en: 10.1136/annrheumdis-2012-203090.
Yoo, Dae Hyun; Racewicz, Artur; Brzezicki, Jan; Yatsyshyn, Roman; Arteaga, Edgardo Tobias; Baranauskaite, Asta; Abud-Mendoza, Carlos; Navarra, Sandra; Kadinov, Vladimir; Sariego, Irmgadt Goecke; Hong, Seung Suh; Lee, Sung Young; Park, Won (2016) A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. En: Arthritis Research & Therapy. Vol. 18; pp. 82 1478-6362; Disponible en: 10.1186/s13075-016-0981-6.
Emery, P.; Deodhar, A.; Rigby, W. F.; Isaacs, J. D.; Combe, B.; Racewicz, A. J.; Latinis, K.; Abud-Mendoza, C.; Szczepanski, L. J.; Roschmann, R. A.; Chen, A.; Armstrong, G. K.; Douglass, W.; Tyrrell, H. (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). En: Annals of the Rheumatic Diseases. Vol. 69; No. 9; pp. 1629-1635; 1468-2060; Disponible en: 10.1136/ard.2009.119933.
Instituto Nacional de medicamentos y alimentos INVIMA (2015) INFORME DE ANÁLISIS DE EVENTOS ADVERSOS SERIOS NACIONALES EN ENSAYOS CLÍNICOS CON MEDICAMENTOS REPORTADOS EN EL AÑO 2015. Disponible en: https://www.invima.gov.co/documents/20143/790891/2015Informe+EASa+2015.pdf/dbb641ef-616e-661d-ecf4-0b77fa9c863e.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Reimold, Andreas M. (2012) The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. En: Open Access Rheumatology: Research and Reviews. Vol. 4; pp. 33-47; 1179-156X; Disponible en: 10.2147/OARRR.S14569.
Chen, Y.-F.; Jobanputra, P.; Barton, P.; Jowett, S.; Bryan, S.; Clark, W.; Fry-Smith, A.; Burls, A. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. En: Health Technology Assessment (Winchester, England). Vol. 10; No. 42; pp. iii-iv, xi-xiii, 1-229; 1366-5278; Disponible en: 10.3310/hta10420.
Cvetkovic, Risto S.; Scott, Lesley J. (2006) Adalimumab: a review of its use in adult patients with rheumatoid arthritis. En: BioDrugs. pp. 293-311; Consultado en: 2020/03/09/00:13:53. Disponible en: https://pesquisa.bvsalud.org/portal/resource/es/mdl-17025376.
Markus, Richard; McBride, Helen J.; Ramchandani, Monica; Chow, Vincent; Liu, Jennifer; Mytych, Dan; Fanjiang, Gary (2019) A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501. En: Advances in Therapy. Vol. 36; No. 8; pp. 1833-1850; 1865-8652; Disponible en: 10.1007/s12325-019-00979-6.
Cohen, Stanley; Genovese, Mark C.; Choy, Ernest; Perez-Ruiz, Fernando; Matsumoto, Alan; Pavelka, Karel; Pablos, Jose L.; Rizzo, Warren; Hrycaj, Pawel; Zhang, Nan; Shergy, William; Kaur, Primal (2017) Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. En: Annals of the Rheumatic Diseases. Vol. 76; No. 10; pp. 1679-1687; 1468-2060; Disponible en: 10.1136/annrheumdis-2016-210459.
Cohen, Stanley; Pablos, Jose L.; Pavelka, Karel; Müller, Gerard Anton; Matsumoto, Alan; Kivitz, Alan; Wang, Hui; Krishnan, Eswar (2019) An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. En: Arthritis Research & Therapy. Vol. 21; No. 1; pp. 84 1478-6362; Disponible en: 10.1186/s13075-019-1857-3.
Pelechas, Eleftherios; Voulgari, Paraskevi V.; Drosos, Alexandros A. (2018) ABP 501 for the treatment of rheumatoid arthritis. En: Expert Opinion on Biological Therapy. Vol. 18; No. 3; pp. 317-322; 1744-7682; Disponible en: 10.1080/14712598.2018.1430760.
Sivendran, Renuka; Ramírez, José; Ramchandani, Monica; Liu, Jennifer (2018) Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab. En: Immunotherapy. Vol. 10; No. 11; pp. 1011-1021; 1750-7448; Disponible en: 10.2217/imt-2018-0040.
Liu, Jennifer; Eris, Tamer; Li, Cynthia; Cao, Shawn; Kuhns, Scott (2016) Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. En: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. Vol. 30; No. 4; pp. 321-338; 1179-190X; Disponible en: 10.1007/s40259-016-0184-3.
Kaur, Primal; Chow, Vincent; Zhang, Nan; Moxness, Michael; Kaliyaperumal, Arunan; Markus, Richard (2017) A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. En: Annals of the Rheumatic Diseases. Vol. 76; No. 3; pp. 526-533; 1468-2060; Disponible en: 10.1136/annrheumdis-2015-208914.
Norman, Peter (2017) Humira®: recent developments. En: Pharmaceutical Patent Analyst. Vol. 6; No. 3; pp. 89-90; 2046-8962; Disponible en: 10.4155/ppa-2017-0012.
Advanced Search | Cochrane Library. Consultado en: 2020/03/23/13:47:36. Disponible en: https://www.cochranelibrary.com/advanced-search.
Immunogenicity associated with a transition from adalimumab reference product to ABP 501 in patients with rheumatoid arthritis | Cochrane Library. Consultado en: 2020/03/23/14:25:19. Disponible en: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01647590/full.
Velayudhan, Jyoti; Chen, Yuh-feng; Rohrbach, Amanda; Pastula, Christina; Maher, Gwen; Thomas, Heather; Brown, Ryan; Born, Teresa L. (2016) Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab. En: BioDrugs. Vol. 30; No. 4; pp. 339-351; 1179-190X; Consultado en: 2020/03/30/01:58:25. Disponible en: https://doi.org/10.1007/s40259-016-0185-2. Disponible en: 10.1007/s40259-016-0185-2.
González, Martha Lucía; Rueda, Jorge; González, Herman; Cantor, Erika; Martínez, Alexander (2016) Artritis reumatoide temprana: resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia. En: Revista Colombiana de Reumatología. Vol. 23; No. 3; pp. 148-154; 0121-8123; Consultado en: 2020/04/09/15:59:24. Disponible en: http://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-artritis-reumatoide-temprana-resultados-clinicos-S0121812316300275. Disponible en: 10.1016/j.rcreu.2016.04.004.
RODRÍGUEZ CORTES, LAURA ANDREA (2015) EVALUACION ECONOMICA DE MEDICAMENTOS BIOLOGICOS UTILIZADOS EN EL TRATAMIENTO DE TERCERA LINEA PARA ARTRITIS REUMATOIDE EN COLOMBIA. : Tesis Grado, UNIVERSIDAD DE CIENCIAS APLICADAS Y AMBIENTALES; Disponible en: https://repository.udca.edu.co/bitstream/11158/330/1/EVALUACION%20ECONOMICA%20DE%20MEDICAMENTOS%20BIOLOGICOS%20UTILIZADOS%20EN%20EL%20TRATAMIENTO%20DE%20TERCERA%20LINEA%20PAR.pdf.
Gabriel, Sherine E.; Michaud, Kaleb (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. En: Arthritis Research & Therapy. Vol. 11; No. 3; pp. 229 1478-6362; Disponible en: 10.1186/ar2669.
Combe, B.; Lukas, C.; Morel, J. (2016) Artritis reumatoide del adulto: estrategias terapéuticas. En: EMC. Vol. 49; No. 2; pp. 1-24; 1286-935X; Consultado en: 2020/04/09/16:07:44. Disponible en: http://www.sciencedirect.com/science/article/pii/S1286935X16782438. Disponible en: 10.1016/S1286-935X(16)78243-8.
Grupo GUIPCAR de trabajo de la GPC para el Manejo de Pacientes con Artritis Reumatoide (2019) Guía de Práctica Clínica para el Manejo de los Pacientes con Artritis Reumatoide. En: SER. Consultado en: 2020/04/09/16:08:59. Disponible en: https://www.ser.es/guipcar/.
Malhan, Simten; Pay, Salih; Ataman, Sebnem; Dalkilic, Ediz; Dinc, Ayhan; Erken, Eren; Ertenli, Ihsan; Ertugrul, Esin; Gogus, Feride; Hamuryudan, Vedat; Inanc, Murat; Karaarslan, Yasar; Karadag, Omer; Karakoc, Yuksel; Keskin, Goksal; Kisacik, Bunyamin; Kiraz, Sedat; Oksel, Fahrettin; Oksuz, Ergun; Pirildar, Timur; Sari, Ismail; Soy, Mehmet; Senturk, Taskin; Taylan, Ali (2012) The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. En: Clinical and Experimental Rheumatology. Vol. 30; No. 2; pp. 202-207; 0392-856X
Gulácsi, László; Brodszky, Valentin; Baji, Petra; Kim, HoUng; Kim, Su Yeon; Cho, Yu Young; Péntek, Márta (2015) Biosimilars for the management of rheumatoid arthritis: economic considerations. En: Expert Review of Clinical Immunology. Vol. 11 Suppl 1; pp. S43-52; 1744-8409; Disponible en: 10.1586/1744666X.2015.1090313.
Mysler, Eduardo; Pineda, Carlos; Horiuchi, Takahiko; Singh, Ena; Mahgoub, Ehab; Coindreau, Javier; Jacobs, Ira (2016) Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. En: Rheumatology International. Vol. 36; No. 5; pp. 613-625; 1437-160X; Disponible en: 10.1007/s00296-016-3444-0.
Collazo Herrera, Manuel; Sosa Lorenzo, Irma (2011) La farmacoeconomía: Debe ser de interés para evaluar la eficiencia en la toma de decisiones?. En: Revista Colombiana de Ciencias Químico. Vol. 40; No. 1; pp. 54-66; 0034-7418; Consultado en: 2020/04/09/16:30:09. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0034-74182011000100004&lng=en&nrm=iso&tlng=es.
Cohen, Hillel P.; Blauvelt, Andrew; Rifkin, Robert M.; Danese, Silvio; Gokhale, Sameer B.; Woollett, Gillian (2018) Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. En: Drugs. Vol. 78; No. 4; pp. 463-478; 1179-1950; Disponible en: 10.1007/s40265-018-0881-y.
Messori, Andrea; Trippoli, Sabrina; Marinai, Claudio (2017) Network meta-analysis as a tool for improving the effectiveness assessment of biosimilars based on both direct and indirect evidence: application to infliximab in rheumatoid arthritis. En: European Journal of Clinical Pharmacology. Vol. 73; No. 4; pp. 513-514; 1432-1041; Disponible en: 10.1007/s00228-016-2177-z.
Larráyoz, Beatriz; Concepto, regulación y controversias en su utilización. pp. 11
Londoño, John; Peláez-Ballestas, Ingris; Cuervo, Francy; Angarita, Ignacio; Giraldo, Rodrigo; Rueda, Juan Camilo; Ballesteros, Jesús Giovanny; Baquero, Roberto; Forero, Elías; Cardiel, Mario; Saldarriaga, Eugenia; Vásquez, Andrés; Arias, Sofía; Valero, Lina; González, Camilo; Ramírez, Javier; Toro, Carlos; Santos, Ana María (2018) Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. En: Revista Colombiana de Reumatología. Vol. 25; No. 4; pp. 245-256; 0121-8123; Consultado en: 2020/04/09/16:39:30. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0121-81232018000400245&lng=en&nrm=iso&tlng=es. Disponible en: 10.1016/j.rcreu.2018.08.003.
Sharma, Shefali Khanna (2017) Use of Biologics and Biosimilars in Rheumatology. En: The Journal of the Association of Physicians of India. Vol. 65; No. 5 Suppl; pp. 9-14; 0004-5772
Kowalik, Krzysztof; Węgierska, Małgorzata; Barczyńska, Tacjana; Jeka, Sławomir (2018) Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. En: Reumatologia. Vol. 56; No. 6; pp. 340-345; 0034-6233; Disponible en: 10.5114/reum.2018.80710.
Weinblatt, M E; Keystone, E C; Furst, D E; Kavanaugh, A F; Chartash, E K; Segurado, O G (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. En: Annals of the Rheumatic Diseases. Vol. 65; No. 6; pp. 753-759; 0003-4967; Consultado en: 2020/04/09/16:54:36. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798163/. Disponible en: 10.1136/ard.2005.044404.
Bang, Lynne M.; Keating, Gillian M. (2004) Adalimumab. En: BioDrugs. Vol. 18; No. 2; pp. 121-139; 1179-190X; Consultado en: 2020/04/09/17:00:27. Disponible en: https://doi.org/10.2165/00063030-200418020-00005. Disponible en: 10.2165/00063030-200418020-00005.
Carmona, Loreto; Cross, Marita; Williams, Ben; Lassere, Marissa; March, Lyn (2010) Rheumatoid arthritis. En: Best Practice & Research. Clinical Rheumatology. Vol. 24; No. 6; pp. 733-745; 1532-1770; Disponible en: 10.1016/j.berh.2010.10.001.
Serra López-Matencio, José M.; Morell Baladrón, Alberto; Castañeda, Santos (2017) Fármacos biosimilares: un nuevo escenario en las terapias biológicas. En: Reumatología Clínica. Vol. 13; No. 5; pp. 287-293; 1699-258X; Consultado en: 2020/04/10/14:49:03. Disponible en: http://www.sciencedirect.com/science/article/pii/S1699258X16300572. Disponible en: 10.1016/j.reuma.2016.05.013.
El medicamento contra la artritis Humira, el más vendido del mundo. Consultado en: 2020/04/10/16:24:13. Disponible en: https://www.plantadoce.com/entorno/el-medicamento-contra-la-artritis-humira-el-mas-vendido-del-mundo.html.
Breedveld, Ferdinand C.; Weisman, Michael H.; Kavanaugh, Arthur F.; Cohen, Stanley B.; Pavelka, Karel; van Vollenhoven, Ronald; Sharp, John; Perez, John L.; Spencer-Green, George T. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. En: Arthritis and Rheumatism. Vol. 54; No. 1; pp. 26-37; 0004-3591; Disponible en: 10.1002/art.21519.
Fiorino, Gionata; Gilardi, Daniela; Correale, Carmen; Furfaro, Federica; Roda, Giulia; Loy, Laura; Argollo, Marjorie; Allocca, Mariangela; Peyrin-Biroulet, Laurent; Danese, Silvio (2019) Biosimilars of adalimumab: the upcoming challenge in IBD. En: Expert Opinion on Biological Therapy. Vol. 19; No. 10; pp. 1023-1030; 1471-2598; Consultado en: 2020/05/01/21:59:52. Disponible en: https://doi.org/10.1080/14712598.2019.1564033. Disponible en: 10.1080/14712598.2019.1564033.
Azevedo, Valderilio Feijó; Babini, Alejandra; Caballero-Uribe, Carlo V.; Castañeda-Hernández, Gilberto; Borlenghi, Cecilia; Jones, Heather E. (2019) Practical Guidance on Biosimilars, With a Focus on Latin America. En: Journal of Clinical Rheumatology. Vol. 25; No. 2; pp. 91-100; 1076-1608; Consultado en: 2020/05/02/16:12:27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392209/. Disponible en: 10.1097/RHU.0000000000000881.
Fondo Colombiano de enfermedades de alto costo (CAC) (2020) Situación de la Artritis Reumatoide en Colombia 2019.
Agencia Europea de Medicamentos; Comision Europea (2019) Los biosimilares en la UE. Guia informativa para profesionales sanitarios. En: 2019. pp. 40
Schiff, Michael; Weinblatt, Michael E.; Valente, Robert; Heijde, Désirée van der; Citera, Gustavo; Elegbe, Ayanbola; Maldonado, Michael; Fleischmann, Roy (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. En: Annals of the Rheumatic Diseases. Vol. 73; No. 1; pp. 86-94; 0003-4967, 1468-2060; Consultado en: 2021/02/06/15:59:28. Disponible en: https://ard.bmj.com/content/73/1/86. Disponible en: 10.1136/annrheumdis-2013-203843.
Fleischmann, Roy; Mysler, Eduardo; Hall, Stephen; Kivitz, Alan J.; Moots, Robert J.; Luo, Zhen; DeMasi, Ryan; Soma, Koshika; Zhang, Richard; Takiya, Liza; Tatulych, Svitlana; Mojcik, Christopher; Krishnaswami, Sriram; Menon, Sujatha; Smolen, Josef S.; ORAL Strategy investigators (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. En: Lancet (London, England). Vol. 390; No. 10093; pp. 457-468; 1474-547X; Disponible en: 10.1016/S0140-6736(17)31618-5.
Smolen, Josef S.; Burmester, Gerd-Rüdiger; Combe, Bernard; Curtis, Jeffrey R.; Hall, Stephen; Haraoui, Boulos; van Vollenhoven, Ronald; Cioffi, Christopher; Ecoffet, Cécile; Gervitz, Leon; Ionescu, Lucian; Peterson, Luke; Fleischmann, Roy (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. En: Lancet (London, England). Vol. 388; No. 10061; pp. 2763-2774; 1474-547X; Disponible en: 10.1016/S0140-6736(16)31651-8.
Silman, A. J.; Hochberg, M. C. (2001) Epidemiology of the rheumatic diseases. En: Epidemiology of the rheumatic diseases. No. Ed. 2; Consultado en: 2021/02/06/16:17:19. Disponible en: https://www.cabdirect.org/cabdirect/abstract/20033069305.
Zeidler, Henning (2012) The need to better classify and diagnose early and very early rheumatoid arthritis. En: The Journal of Rheumatology. Vol. 39; No. 2; pp. 212-217; 0315-162X; Disponible en: 10.3899/jrheum.110967.
Fernández-Ávila, Daniel G.; Rincón-Riaño, Diana N.; Bernal-Macías, Santiago; Gutiérrez Dávila, Juan M.; Rosselli, Diego (2019) Prevalencia de la artritis reumatoide en Colombia según información del Sistema Integral de Información de la Protección Social. En: Revista Colombiana de Reumatología. Vol. 26; No. 2; pp. 83-87; 01218123; Consultado en: 2021/02/06/16:40:56. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0121812319300167. Disponible en: 10.1016/j.rcreu.2019.01.003.
Funovits, Julia; Aletaha, Daniel; Bykerk, Vivian; Combe, Bernard; Dougados, Maxime; Emery, Paul; Felson, David; Hawker, Gillian; Hazes, Joanna M.; Huizinga, Tom; Kay, Jonathan; Kvien, Tore K.; Smolen, Josef S.; Symmons, Deborah; Tak, Paul P.; Silman, Alan (2010) The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. En: Annals of the Rheumatic Diseases. Vol. 69; No. 9; pp. 1589-1595; 1468-2060; Disponible en: 10.1136/ard.2010.130310.
Aletaha, Daniel; Neogi, Tuhina; Silman, Alan J.; Funovits, Julia; Felson, David T.; Bingham, Clifton O.; Birnbaum, Neal S.; Burmester, Gerd R.; Bykerk, Vivian P.; Cohen, Marc D.; Combe, Bernard; Costenbader, Karen H.; Dougados, Maxime; Emery, Paul; Ferraccioli, Gianfranco; Hazes, Johanna M. W.; Hobbs, Kathryn; Huizinga, Tom W. J.; Kavanaugh, Arthur; Kay, Jonathan; Kvien, Tore K.; Laing, Timothy; Mease, Philip; Ménard, Henri A.; Moreland, Larry W.; Naden, Raymond L.; Pincus, Theodore; Smolen, Josef S.; Stanislawska-Biernat, Ewa; Symmons, Deborah; Tak, Paul P.; Upchurch, Katherine S.; Vencovský, Jirí; Wolfe, Frederick; Hawker, Gillian (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. En: Arthritis and Rheumatism. Vol. 62; No. 9; pp. 2569-2581; 1529-0131; Disponible en: 10.1002/art.27584.
Bizzaro, Nicola; Bartoloni, Elena; Morozzi, Gabriella; Manganelli, Stefania; Riccieri, Valeria; Sabatini, Paola; Filippini, Matteo; Tampoia, Marilina; Afeltra, Antonella; Sebastiani, Giandomenico; Alpini, Claudia; Bini, Vittorio; Bistoni, Onelia; Alunno, Alessia; Gerli, Roberto; the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group) (2013) Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. En: Arthritis Research & Therapy. Vol. 15; No. 1; pp. R16 1478-6354; Consultado en: 2021/02/06/17:00:33. Disponible en: http://arthritis-research.biomedcentral.com/articles/10.1186/ar4148. Disponible en: 10.1186/ar4148.
Aletaha, Daniel; Alasti, Farideh; Smolen, Josef S. (2011) Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. En: Annals of the Rheumatic Diseases. Vol. 70; No. 11; pp. 1975-1980; 1468-2060; Disponible en: 10.1136/ard.2011.153734.
Singh, Jasvinder A.; Furst, Daniel E.; Bharat, Aseem; Curtis, Jeffrey R.; Kavanaugh, Arthur F.; Kremer, Joel M.; Moreland, Larry W.; O'Dell, James; Winthrop, Kevin L.; Beukelman, Timothy; Bridges, S. Louis; Chatham, W. Winn; Paulus, Harold E.; Suarez-Almazor, Maria; Bombardier, Claire; Dougados, Maxime; Khanna, Dinesh; King, Charles M.; Leong, Amye L.; Matteson, Eric L.; Schousboe, John T.; Moynihan, Eileen; Kolba, Karen S.; Jain, Archana; Volkmann, Elizabeth R.; Agrawal, Harsh; Bae, Sangmee; Mudano, Amy S.; Patkar, Nivedita M.; Saag, Kenneth G. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. En: Arthritis Care & Research. Vol. 64; No. 5; pp. 625-639; 2151-4658; Disponible en: 10.1002/acr.21641.
Linden, Michael P. M. van der; Cessie, Saskia le; Raza, Karim; Woude, Diane van der; Knevel, Rachel; Huizinga, Tom W. J.; Mil, Annette H. M. van der Helm-van (2010) Long-term impact of delay in assessment of patients with early arthritis. En: Arthritis & Rheumatism. Vol. 62; No. 12; pp. 3537-3546; 1529-0131; Consultado en: 2021/02/06/17:11:19. Disponible en: http://onlinelibrary.wiley.com/doi/abs/10.1002/art.27692. Disponible en: https://doi.org/10.1002/art.27692.
Verstappen, S. M. M.; Jacobs, J. W. G.; van der Veen, M. J.; Heurkens, A. H. M.; Schenk, Y.; ter Borg, E. J.; Blaauw, A. a. M.; Bijlsma, J. W. J.; Utrecht Rheumatoid Arthritis Cohort study group (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). En: Annals of the Rheumatic Diseases. Vol. 66; No. 11; pp. 1443-1449; 0003-4967; Disponible en: 10.1136/ard.2007.071092.
Curtis, Jeffrey R.; Singh, Jasvinder A. (2011) Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. En: Clinical Therapeutics. Vol. 33; No. 6; pp. 679-707; 1879-114X; Disponible en: 10.1016/j.clinthera.2011.05.044.
Bernal-Camargo, Diana Rocío; Gaitán-Bohórquez, Julio César; León-Robayo, Édgar Iván (2018) Medicamentos biosimilares en Colombia: una revisión desde el consumo informado. En: Revista Ciencias de la Salud. Vol. 16; No. 2; pp. 311 2145-4507, 1692-7273; Consultado en: 2021/02/06/17:36:33. Disponible en: https://revistas.urosario.edu.co/index.php/revsalud/article/view/6772. Disponible en: 10.12804/revistas.urosario.edu.co/revsalud/a.6772.
Goel, Niti; Chance, Kamali (2017) Biosimilars in rheumatology: understanding the rigor of their development. En: Rheumatology (Oxford, England). Vol. 56; No. 2; pp. 187-197; 1462-0332; Disponible en: 10.1093/rheumatology/kew206.
Brinks, Vera; Jiskoot, Wim; Schellekens, Huub (2011) Immunogenicity of therapeutic proteins: the use of animal models. En: Pharmaceutical Research. Vol. 28; No. 10; pp. 2379-2385; 1573-904X; Disponible en: 10.1007/s11095-011-0523-5.
Jullien, D. (2012) Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis. En: Annales de Dermatologie et de Vénéréologie. Un œil neuf sur le psoriasis; Vol. 139; pp. S58-S67; 0151-9638; Consultado en: 2021/02/09/01:06:50. Disponible en: https://www.sciencedirect.com/science/article/pii/S0151963812701126. Disponible en: 10.1016/S0151-9638(12)70112-6.
Carrascosa, J. M. (2013) Inmunogenicidad en terapia biológica. Implicaciones en Dermatología. En: Actas Dermo-Sifiliográficas. Vol. 104; No. 6; pp. 471-479; 0001-7310; Consultado en: 2021/02/09/01:07:38. Disponible en: https://www.sciencedirect.com/science/article/pii/S0001731013000999. Disponible en: 10.1016/j.ad.2013.02.005.
Pani, Luca; Montilla, Simona; Pimpinella, Giuseppe; Bertini Malgarini, Renato (2013) Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. En: Expert Opinion on Biological Therapy. Vol. 13; No. 10; pp. 1343-1346; 1744-7682; Disponible en: 10.1517/14712598.2013.815722.
Kugler, Adriana D. (2000) The Incidence of Job Security Regulations on Labor Market Flexibility and Compliance in Colombia: Evidence from the 1990 Reform. Rochester, NY: Social Science Research Network; ID 1814666; Consultado en: 2021/03/14/14:29:00. Disponible en: https://papers.ssrn.com/abstract=1814666.
Kugler, Adriana D. (2000) The Incidence of Job Security Regulations on Labor Market Flexibility and Compliance in Colombia: Evidence from the 1990 Reform. Rochester, NY: Social Science Research Network; ID 1814666; Consultado en: 2021/03/14/14:29:41. Disponible en: https://papers.ssrn.com/abstract=1814666.
Targan, S. R.; Hanauer, S. B.; van Deventer, S. J.; Mayer, L.; Present, D. H.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. En: The New England Journal of Medicine. Vol. 337; No. 15; pp. 1029-1035; 0028-4793; Disponible en: 10.1056/NEJM199710093371502.
Maini, R. N.; Breedveld, F. C.; Kalden, J. R.; Smolen, J. S.; Davis, D.; Macfarlane, J. D.; Antoni, C.; Leeb, B.; Elliott, M. J.; Woody, J. N.; Schaible, T. F.; Feldmann, M. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. En: Arthritis and Rheumatism. Vol. 41; No. 9; pp. 1552-1563; 0004-3591; Disponible en: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.
St Clair, E. William; Wagner, Carrie L.; Fasanmade, Adedigbo A.; Wang, Benjamin; Schaible, Thomas; Kavanaugh, Arthur; Keystone, Edward C. (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. En: Arthritis and Rheumatism. Vol. 46; No. 6; pp. 1451-1459; 0004-3591; Disponible en: 10.1002/art.10302.
Anonymous (2018) Remsima. En: European Medicines Agency. Consultado en: 2021/05/26/01:08:01. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima.
Park, Won; Hrycaj, Pawel; Jeka, Slawomir; Kovalenko, Volodymyr; Lysenko, Grygorii; Miranda, Pedro; Mikazane, Helena; Gutierrez-Ureña, Sergio; Lim, MieJin; Lee, Yeon-Ah; Lee, Sang Joon; Kim, HoUng; Yoo, Dae Hyun; Braun, Jürgen (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. En: Annals of the Rheumatic Diseases. Vol. 72; No. 10; pp. 1605-1612; 0003-4967, 1468-2060; Consultado en: 2021/05/26/01:09:20. Disponible en: https://ard.bmj.com/content/72/10/1605. Disponible en: 10.1136/annrheumdis-2012-203091.
Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13. En: ACR Meeting Abstracts. Consultado en: 2021/05/26/01:10:27. Disponible en: https://acrabstracts.org/abstract/efficacy-and-safety-of-ct-p13-infliximab-biosimilar-over-two-years-in-patients-with-ankylosing-spondylitis-comparison-between-continuing-with-ct-p13-and-switching-from-infliximab-to-ct-p13/.
Goll, G. L.; Jørgensen, K. K.; Sexton, J.; Olsen, I. C.; Bolstad, N.; Haavardsholm, E. A.; Lundin, K. E. A.; Tveit, K. S.; Lorentzen, M.; Berset, I. P.; Fevang, B. T. S.; Kalstad, S.; Ryggen, K.; Warren, D. J.; Klaasen, R. A.; Asak, Ø; Baigh, S.; Blomgren, I. M.; Brenna, Ø; Bruun, T. J.; Dvergsnes, K.; Frigstad, S. O.; Hansen, I. M.; Hatten, I. S. H.; Huppertz-Hauss, G.; Henriksen, M.; Hoie, S. S.; Krogh, J.; Midtgard, I. P.; Mielnik, P.; Moum, B.; Noraberg, G.; Poyan, A.; Prestegård, U.; Rashid, H. U.; Strand, E. K.; Skjetne, K.; Seeberg, K. A.; Torp, R.; Ystrøm, C. M.; Vold, C.; Zettel, C. C.; Waksvik, K.; Gulbrandsen, B.; Hagfors, J.; Mørk, C.; Jahnsen, J.; Kvien, T. K. (2019) Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. En: Journal of Internal Medicine. Vol. 285; No. 6; pp. 653-669; 1365-2796; Disponible en: 10.1111/joim.12880.
Yoo, Dae Hyun; Prodanovic, Nenad; Jaworski, Janusz; Miranda, Pedro; Ramiterre, Edgar; Lanzon, Allan; Baranauskaite, Asta; Wiland, Piotr; Abud-Mendoza, Carlos; Oparanov, Boycho; Smiyan, Svitlana; Kim, HoUng; Lee, Sang Joon; Kim, SuYeon; Park, Won (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. En: Annals of the Rheumatic Diseases. Vol. 76; No. 2; pp. 355-363; 1468-2060; Disponible en: 10.1136/annrheumdis-2015-208786.
Yoo, Dae Hyun; Hrycaj, Pawel; Miranda, Pedro; Ramiterre, Edgar; Piotrowski, Mariusz; Shevchuk, Sergii; Kovalenko, Volodymyr; Prodanovic, Nenad; Abello-Banfi, Mauricio; Gutierrez-Ureña, Sergio; Morales-Olazabal, Luis; Tee, Michael; Jimenez, Renato; Zamani, Omid; Lee, Sang Joon; Kim, HoUng; Park, Won; Müller-Ladner, Ulf (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. En: Annals of the Rheumatic Diseases. Vol. 72; No. 10; pp. 1613-1620; 1468-2060; Disponible en: 10.1136/annrheumdis-2012-203090.
Yoo, Dae Hyun; Racewicz, Artur; Brzezicki, Jan; Yatsyshyn, Roman; Arteaga, Edgardo Tobias; Baranauskaite, Asta; Abud-Mendoza, Carlos; Navarra, Sandra; Kadinov, Vladimir; Sariego, Irmgadt Goecke; Hong, Seung Suh; Lee, Sung Young; Park, Won (2016) A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. En: Arthritis Research & Therapy. Vol. 18; pp. 82 1478-6362; Disponible en: 10.1186/s13075-016-0981-6.
Emery, P.; Deodhar, A.; Rigby, W. F.; Isaacs, J. D.; Combe, B.; Racewicz, A. J.; Latinis, K.; Abud-Mendoza, C.; Szczepanski, L. J.; Roschmann, R. A.; Chen, A.; Armstrong, G. K.; Douglass, W.; Tyrrell, H. (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). En: Annals of the Rheumatic Diseases. Vol. 69; No. 9; pp. 1629-1635; 1468-2060; Disponible en: 10.1136/ard.2009.119933.
Instituto Nacional de medicamentos y alimentos INVIMA (2015) INFORME DE ANÁLISIS DE EVENTOS ADVERSOS SERIOS NACIONALES EN ENSAYOS CLÍNICOS CON MEDICAMENTOS REPORTADOS EN EL AÑO 2015. Disponible en: https://www.invima.gov.co/documents/20143/790891/2015Informe+EASa+2015.pdf/dbb641ef-616e-661d-ecf4-0b77fa9c863e.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: No existe evidencia científica de estudios comparadores entre biosimilares, que demuestren la seguridad y eficacia, siendo esto relevante para que clínicos y aseguradores se sientan respaldados en el momento de adquirir y prescribir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1339d4aa08fd8533dd6296f3bc727b2
https://repository.urosario.edu.co/handle/10336/31763
https://repository.urosario.edu.co/handle/10336/31763
